Back to Search

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Palo Alto, California, 94305
Omaha, Nebraska, 68130
San Diego, California, 92093
Los Angeles, California, 90095
Los Angeles, California, 90033
Search ended 05/31/2024

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Eligibility

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical

Ages Eligible for Study Min Age: 18 years - Max Age: N/A
Sexes Eligible for Study All
Accepts Healthy Volunteers No

Visit ClinicalTrials.Gov for more information
Support nonprofit organizations through participating in clinical trials at no cost to you
You may also be interested in
Grand Junction, CO and more
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
Cytomegalovirus Read more
Rockville, Maryland and more
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
Seasonal Influenza Read more
Oklahoma City, Oklahoma and more
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Cytomegalovirus Infection Read more